Abaloparatide-SC improves trabecular microarchitecture as assessed by trabecular bone score (TBS): a 24-week randomized clinical trial

SUMMARY: In a phase 2 trial of 222 postmenopausal women with osteoporosis aged 55 to 85 years randomized to one of three different doses of abaloparatide-SC, subcutaneous teriparatide, or placebo for 24 weeks, abaloparatide-SC resulted in improvements in skeletal microarchitecture as measured by the...

Descripción completa

Detalles Bibliográficos
Autores principales: Bilezikian, J. P., Hattersley, G., Fitzpatrick, L. A., Harris, A. G., Shevroja, E., Banks, K., Leder, B. Z., Zanchetta, J. R., Hans, D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer London 2017
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5818587/
https://www.ncbi.nlm.nih.gov/pubmed/29167971
http://dx.doi.org/10.1007/s00198-017-4304-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5818587/
https://www.ncbi.nlm.nih.gov/pubmed/29167971
http://dx.doi.org/10.1007/s00198-017-4304-9

Ejemplares similares